B. Zhu

Shuhang Wang, Junling Li, Yanhua Tian, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel

Jing Zhao, Guoqiang Wang, Jun Zhao, 2019, JAMA oncology.

Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19

Chengliang Zhu, Jun Wang, Bicheng Zhang, 2020, medRxiv.

Mutational burden and chromosomal aneuploidy synergistically predict survival from radiotherapy in non-small cell lung cancer

Y. Wan, Kaiyu Qian, Ji He, 2021, Communications Biology.

Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation

Jun Wang, Bicheng Zhang, B. Zhu, 2020, Frontiers in Oncology.

Attitudes and Practices of Immune Checkpoint Inhibitors in Chinese Patients With Cancer: A National Cross-Sectional Survey

Yongmei Yin, Baocheng Wang, Hao Wu, 2021, Frontiers in Pharmacology.

中国非小细胞肺癌免疫检查点抑制剂治疗专家共识（2020年版）

Jingjing Liu, Ying Cheng, B. Han, 2021, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

From diagnosis to therapy in lung cancer: management of CT detected pulmonary nodules, a summary of the 2015 Chinese-German Lung Cancer Expert Panel.

R. Pirker, W. Voigt, T. Henzler, 2016, Translational lung cancer research.

Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19

Chengliang Zhu, Jun Wang, Bicheng Zhang, 2020, Frontiers in Molecular Biosciences.

Ef ﬁ cacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/ Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study

T. Wang, D. Zhong, Yanqiu Zhao, 2022 .

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study

Zhimin Zhang, Z. Ruan, Ge Wang, 2017, BMC Cancer.

Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC

H. Popper, R. Rosell, N. van Zandwijk, 2021, Theranostics.

Safety, Efficacy and Pharmacokinetics of Rezivertinib (BPI-7711) in Advanced Non-Small Cell Lung Cancer Patients with EGFR T790M Mutation: a Phase 1 Dose-Escalation and Dose-Expansion Study.

Yanqiu Zhao, Y. Shu, Gong-yan Chen, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical characteristics of 82 death cases with COVID-19

Hengcheng Zhu, Xiongfei Wu, Jun Wang, 2020, medRxiv.

Zhimin Zhang, Ge Wang, Z. Ruan, 2017, BMC Cancer.

Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib

C. Yi, Wei Wu, M. Zhuo, 2020, Frontiers in Oncology.

Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations

Wenfeng Li, Baocheng Wang, J. Wang, 2023, Therapeutic advances in medical oncology.

Meta-analysis of the literature: Neoadjuvant chemotherapy versus surgery alone in non-small cell lung cancer

B. Zhu, L. Dan, Z. Chen, 2008 .

SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, for advanced NSCLC with EGFR mutations: Data from a multicenter phase 1 study.

Yunpeng Liu, Yuankai Shi, Jifeng Feng, 2021 .

MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC

Y. Wang, P. Keegan, D. Zhong, 2021, Journal of Thoracic Oncology.

A nomogram prediction of outcome in patients with COVID‐19 based on individual characteristics incorporating immune response‐related indicators

Xiaoshuai Zhang, Jun Wang, Bicheng Zhang, 2021, Journal of medical virology.